BioAmber Inc. announced today that the Company has entered into a mutual separation agreement with Mario Saucier, in connection with his departure from his role of Chief Financial Officer effective March 28, 2017.
BioAmber intends to initiate a search for a replacement CFO and until such time, Raymond J. Land, the current Chairman of the Board, has been appointed as the company’s interim Chief Financial Officer effective March 28, 2017.
Mr. Land has served on BioAmber’s Board since 2011. Prior to his retirement, Mr. Land served as Sr. VP and CFO of Clarient, Inc., a cancer diagnostics company, Sr. VP and CFO of Safeguard Scientifics, Inc., a venture capital firm, and Sr. VP and CFO for Genencor International Inc., from 1997 until its acquisition in 2005. Mr. Land has also held various positions at Campbell Soup Company Inc. and at Coopers & Lybrand, an accounting firm. – See more at: http://investor.bio-amber.com/#committees
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.